图1. 激酶催化的ATP介导的磷酸化反应过程。
图1. FDA批准小分子激酶抑制剂药物年份数量图。
图2. 部分FDA批准的激酶抑制剂药物分子结构。
图3. 激酶抑制剂常见的芳香杂环结构。
[1] Manning, G. et al. The protein kinase complement of the human genome. Science. 2002, 298, 1912–1934.
[2] Cohen, P. The regulation of protein function by multisite phosphorylation — a 25 year update. Trends Biochem. Sci. 2000, 25, 596–601.
[3] Manning, G., et al. The protein kinase complement of the human genome. Science. 2002, 298, 1912–1934.
[4] Muller, S. et al. The ins and outs of selective kinase inhibitor development. Nat. Chem. Biol. 2015, 11, 818–821.
[5] Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res. 2020, 152, 104609.
[6] Green, K. N. et al. To Kill a Microglia: A Case for CSF1R Inhibitors. Trends in Immunology. 2020, 41, 771–784.
[7] Imatinib Mesylate. The American Society of Health-System Pharmacists.
[8] Wu, P. et al. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015, 36, 422-439.
[9] Keating, J. A. et al. Phosphorylation events during viral infections provide potential therapeutic targets. Rev. Med. Virol. 2012, 22, 166–181.
[10] García-Cárceles, J. et al. Kinase Inhibitors as Underexplored Antiviral Agents. J Med Chem. 2022, 65, 935–954.
[11] Blake, S. et al. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin. Immunol. 2008, 127, 330–339.
[12] Naik, R. R. et al. Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Front. Pharmacol. 2022, 13, 806568.
2024-09-02
2024-09-04
2024-09-23
2024-08-28
2024-09-27
2024-08-27
2024-09-09
近年来,RNA疗法及其在疾病治疗中的潜力备受关注,今年诺贝尔生理学或医学奖授予微小RNA(microRNA)领域的研究更是将这一热度推向高峰。在新药研发蓬勃发展的今天,小核酸药物被视为继小分子药和抗体药之后的“第三次制药浪潮”的关键力量。
作者:崔芳菲
评论
加载更多